We are thrilled to share a major milestone in the growth of our MAI CDMO platform – VIVEbiotech, an industry leader in lentiviral vectors manufacturing and gene therapy, is now officially joining forces with us!
This collaboration marks an important step forward for both organizations. VIVEbiotech’s deep expertise in Advanced Therapy Medicinal Products (ATMP), particularly in the production of lentiviral vectors, positions them as a key player in the rapidly evolving gene therapy landscape. Together, we aim to leverage their cutting-edge capabilities to further enhance the MAI CDMO platform, strengthening our ability to support the development and manufacturing of innovative therapies.
Why is this partnership important?
Expertise in Lentiviral Vectors: VIVEbiotech has extensive experience in the production of lentiviral vectors, a critical component in many gene therapies. This strengthens our platform’s technical foundation in ATMP manufacturing.
Advancing Gene Therapy: As the field of gene therapy continues to evolve, our collaboration will contribute to the development of life-changing treatments by offering high-quality, scalable production processes.
Synergy for Innovation: The combination of MAI CDMO’s robust platform and VIVEbiotech’s specialized knowledge will drive innovative solutions for clients working on breakthrough therapies.
We warmly welcome VIVEbiotech to the MAI CDMO family and look forward to achieving great success together as we embark on this exciting journey. Stay tuned for more updates on our collaborative efforts in the ATMP space!